CreatorsPublishersAdvertisers
View more in
Economy

Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements

Benzinga
 2021-07-20

Cover picture for the articleLineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Overall, 10/12 (83%) of the Cohort 4 patients' treated eyes continued to be at or above baseline...

www.benzinga.com

Comments / 0

Comments / 0